Bioecological and nutritional control of disease: Prebiotics probiotics and synbiotics;Control bioecológico y nutricional de la enfermedad: Prebióticos, probióticos y simbióticos

Nutricion Hospitalaria

Volumn 21, Issue SUPPL. 2, 2006, Pages 73-86

  Bengmark, S ^a   Gil, A ^b,c  

^a Instituto de Hepatología   (Spain)

^b UNIVERSITY OF GRANADA   (Spain)

^c Facultad de Farmacia   (Spain)

Author keywords

Intestinal flora; Lactic acid bacteria; Microbiota; Prebiotics; Probiotics; Synbiotics

Indexed keywords

ANTIINFLAMMATORY AGENT; ANTIOXIDANT; CARCINOGEN; GROWTH FACTOR; LIPID EMULSION; MUTAGENIC AGENT; PREBIOTIC AGENT; PROBIOTIC AGENT; SYNBIOTIC AGENT; TOXIN; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; CHRONIC HEPATITIS; CLINICAL EFFECTIVENESS; CRITICAL ILLNESS; CROHN DISEASE; DIETARY FIBER; DISEASE CONTROL; DRUG EFFICACY; DRUG MECHANISM; GASTROINTESTINAL MOTILITY; HELICOBACTER INFECTION; HUMAN; ILEITIS; ILEUS; IMMUNE RESPONSE; IMMUNOMODULATION; INFECTIOUS DIARRHEA; INNATE IMMUNITY; LACTIC ACID BACTERIUM; LIFESTYLE; MULTIPLE TRAUMA; NONHUMAN; PROTEIN SECRETION; PROTEIN SYNTHESIS; REVIEW; STOMACH PARESIS; ULCERATIVE COLITIS;

EID: 33744899572     PISSN: 02121611     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (100)

1. World Health Organisation. Process for a global strategy on diet, physical activity and health. WHO Geneva February 2003.
2. Bengtsson U, Knutson TW, Knutson L, Dannaeus A, Hallgren R, Ahlstedt S: Increased levels of hyaluronan and albumin after intestinal challenge in adult patients with cow's milk intolerance. Clin Exp Allergy 1996; 26:96-103.
3. Rautava S, Isolauri E: Cow's milk allergy in infants with atopic eczema is associated with aberrant production of interleukin-4 during oral cow's milk challenge. J Pediatr Gastroenterol Nutr 2004; 39:529-535.
4. Bengmark S: Acute and "chronic" phase response - a mother of disease. Clin Nutr 2004; 23:1256-1266.
5. Bengmark S: Bio-ecological Control of the Gastrointestinal Tract: the Role of Microbiota and Supplemented Pro- and Synbiotics. Gastroenterol Clin North Am 2005; 34:413-436.
6. Bengmark S: Impact of nutrition on ageing and disease. Curr Opin Nutr Metab Care 2006; 9:2-7.
7. Arias E, Smith BL Deaths: preliminary data for 2001. Natl Vital Stat Rep 2003; 51:1-44.
8. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR: Epidemiology of severe sepsis in the United States: analysis of incidence, outcome and associated costs of care. Crit Care Med 2001; 29:1303-1310.
9. Bengmark S: Nutritional modulation of acute and "chronic" phase response. Nutrition 2001; 17:489-495.
10. Costa M, Brookes SJ, Hennig GW: Anatomy and physiology of the enteric nervous system. Gut 2000; 47 (Supl. 4):15-19.
11. Lyte M: Microbial endocrinology and infectious disease in the 21st century. Trends in Microbiology 2004; 12:14-20.
12. Groves AC, Griffiths J, Leung F, Meek RN: Plasma catecholamines in patients with serious postoperative infection. Ann Surg 1973; 178:102-107.
13. Kinney KS, Austin CE, Morton DS, Sonnenfeld G: Norepinephrine as a growth stimulating factor in bacteria: Mechanistic studies. Life Science 2000; 67:3075-3085.
14. Alverdy JC, Laughlin RS, Wu L: Influence of the critically ill state on host-pathogen interactions within the intestine: gutderived sepsis redefined. Crit Care Med 2003; 31:598-607.
15. Bengmark S: Bioecological control of perioperative and ITU morbidity. Langenbecks Arch Surg 2004; 389:154.
16. Bengmark S: Bioecological control of inflammation and infection in transplantation. Transplant Rev 2004; 18:38-53.
17. Engelich G, Wright DG, Hartshorn KL: Acquired disorders of phagocyte function complicating medical and surgical illnesses. Clin Infect Dis 2001; 33:2040-2048.
18. Laird AM, Miller PR, Kilgo PD, Meredith JW, Chang MC: Relationship of early hyperglycemia to mortality in trauma patients. J Trauma 2004; 56:1058-1062.
19. Deitch EA, Shorshtein A, Houghton J, Lu Q, Xu D: Inducible nitric oxide synthase knockout mice are resistant to diet-induced loss of gut barrier function and intestinal injury. J Gastrointest Surg 2002; 6:599-605.
20. Hill GE, Frawley WH, Griffith KE, Forestner JE, Minei JP: Allogeneic blood transfusion increases the risk of postoperative bacterial infection: a metaanalysis. J Trauma 2003; 54:908-914.
21. Mayer K, Fegbeutel C, Hattar K, Sibelius U, Krämer HJ, Heuer KU y cols.: ?-3 vs ?-6 lipid emulsions exert differential influence on neutrophils in septic shock patients: impact on plasma fatty acids and lipid mediator generation. Int Care Med 2003; 29:1472-1481.
22. Baines M, Shenkin A: Use of antioxidants in surgery: a measure to reduce postoperative complications. Curr Opin Nutr Metab 2002; 5:665-670.
23. Bengmark S: Curcumin: an atoxic antioxidant and natural NF-?B, COX-2, LOX and iNOS inhibitor - a shield against acute and chronic diseases. J Parent Ent Nutr JPEN 2006; 30:45-51.
24. Bengmark S: Use of Pro-, Pre- and Synbiotics in the ICU - Future options. En: Shikora SA, Martindale RG, Schwaitzberg SD: Nutritional Considerations in the Intensive Care Unit - Science, Rationale and Practice. 2002, Chapter 34. pp. 381-399, Kendall/Hunt Publishing Company, Dubuque, Iowa USA.
25. Bengmark S: Aggressive peri- and intraoperative enteral nutrition - Strategy for the future. En: Shikora SA, Martindale RG, Schwaitzberg SD: Nutritional Considerations in the Intensive Care Unit - Science, Rationale and Practice. 2002, Chapter 33. pp. 365-380, Kendall/Hunt Publishing Company, Dubuque. Iowa USA.
26. Bengmark S: Synbiotics and the mucosal barrier in critically ill patients. Curr Opin Gastroenterol 2005; 21:712-716.
27. Thompson-Chagoyan O, Maldonado J, Gil A: Colonization and impact of disease and other factors on intestinal microbiota. Dig Dis Sci 2006 (in press).
28. Heyman M: Effect of lactic acid bacteria on diarrheal diseases. J Am Coll Nutr 2000; 19 (Supl.):137S-146S.
29. Husebye E, Hellstrom PM, Sundler F, Chen J, Midtvedt T: Influence of microbial species on small intestinal myoelectric activity and transit in germ-free rats. Am J Physiol Gastrointest Liver Physiol 2001; 280:G368-G380.
30. Verdú EF, Bercik P, Bergonzelli GE, Huang XX, Blennerhasset P, Rochat F y cols.: Lactobacillus paracasei normalizes muscle hypercontractility in a murine model of postinfective gut dysfunction. Gastroenterology 2004 Sep; 127(3):826-837.
31. Kelly D Campbell JI, King TP, Grant G, Jansson EA, Coutts AG y cols.: Commensal anaerobic gut bacteria attenuate inflammation by regulating nuclear-cytoplasmic shuttling of PPAR-gamma and Rel A y cols. Nat Immunol 2004; 5:104-112.
32. Bai AP, Ouyang Q, Zhang W, Wang CH, Li SF: Probiotic inhibit TNF-a-induced interleukin-8 secretion of HT29 cells. World J Gastroenterol 2004; 10:455-457.
33. Petrof EO, Kojima K, Ropeleski MJ, Musch MW, Tao Y, De Simone C, Chang EB: Probiotics inhibit nuclear factor-kappaB and induce heat shock proteins in colonic epithelial cells through proteasome inhibition. Gastroenterology 2004; 127:1474-1487.
34. Ma D, Forsythe P, Bienenstock J: Live Lactobacillus Reuteri is essential for inhibitory effect on tumor necrosis factor alpha-induced interleukin-8 expression. Infect Immun 2004; 72:5308-5314.
35. Nurmi JT, Puolakkainen PA, Rautonon NE: Bifidobacterium lactis sp 420 up-regulates cyclooxygenase (Cox)-1 and down-regulates Cox-2 gene expression in a Caco-2 cell culture model. Nutrition and Cancer 2005; 5:83-92.
36. Fink MP: Ethyl pyruvate: a novel treatment for sepsis and shock. Minerva Anestesiol 2004; 70:365-371.
37. Oxman T, Shapira M, Diver A, Klein R, Avazov N, Rabinowitz B: A new method of long-term preventive cardioprotection using Lactobacillus. A J Physiol Heart Circ Physiol 2000; 278:H1717-H1724.
38. Ilkgul O, Bengmark S, Aydede H, Erhan Y, Taneli F, Ulman C: Pretreatment with pro- and synbiotics reduces peritonitis-induce lung injury in rats. In Press.
39. Ilkgul O, Aydede H, Erhan Y, Surucuoglu S, Gazi H, Vatansever S y cols.: Subcutaneous administration of live lactobacillus prevents sepsis-induced lung organ failure in rats. Br J Int Care 2005; 15:52-57.
40. Johansson ML, Molin G, Jeppsson B, Nobaek S, Ahrne S, Bengmark S: Administration of different lactobacillus strains in fermented oatmeal soup: in vivo colonization of human intestinal mucosa and effect on the indigenous microbiota. Applied Environmental Microbiology 1993; 59:15-20.
41. Kruszewska K, Lan J, Lorca G, Yanagisawa N, Marklinder I, Ljungh Å: Selection of lactic acid bacteria as probiotic strains by in vitro tests. Microecology and Therapy 2002; 29:37-51. The proceedings of the XVI International Congress on Microbial Ecology and Disease held Noordwijkerhout, The Netherlands, Oct 2001.
42. Ljungh Å, Lan J-G, Yamagisawa N: Isolation, selection and characteristics of Lactobacillus paracasei ssp paracasei isolate F19. Microbial Ecology in Health and Disease 2002; (Supl. 3):4-6.
43. Borodo TJ, Warren EF, Leis S, Surace R, Ashman O: Treatment of ulcerative colitis using fecal bacteriotherapy. J Clin Gastroenterol 2003; 37:42-47.
44. Borody TJ, Warren EF, Leis SM, Surace R, Ashman O, Siarakas S: Bacteriotherapy using fecal microbiota. Toying with human motions. J Clin Gastroenterol 2004; 38:475-483.
45. Gil A, Rueda R: Interaction of early diet and the development of the immune system. Nutr Res Rev 2002; 15:263-292.
46. Allan SJ, Okoko B, Martínez E, Gregorio G, Dans LF: Probiotics for treating infectious diarrhoea. The Cochrane Database of Systematic Reviews. 2003, issue 4, Art No CD003048 pub2, DOI:10.1002/14651858.CD003048.pub2.
47. Elmer GW, McFarland LV, Surawics, Danko L, Greenberg RN: Behavior of Sacharomyces boulardii in recurrent Clostridium difficile disease patients. Aliment Pharmacol Ther 1999; 13:1663-1668.
48. Thomas MR, Litin SC, Osmon DR, Corr AP, Weaver AL, Lohse CM: Lack of effect of lactobacillus GG on antibiotic-associated diarrhea: a randomized placebo-controlled trial Mayo Clin Proc 2001; 76:883-889.
49. Wullt M, Johansson-Hagslätt ML, Odenholt I: Lactobacillus plantarum 299v for the treatment of recurrent Clostridium difficile-associated diarrhoea: a double blind, placebo-controlled trial. Scand J Infect Dis 2003; 35:365-367.
50. Plein K, Hotz J: Therapeutic effects of Saccharomyces boulardii on mild residual symptoms in a stable phase of Crohn's disease with special respect to chronic diarrhea - a pilot study. Z Gastroenterol 1993; 31:129-134.
51. Guslandi M, Mezzi G, Sorghi M, Testoni PA: Sacharomyces boulardi in maintenance treatment of Crohn's disease. Dig Dis Sci 2000; 45:14662-1464.
52. Malchow HA: Crohn's disease and Escherichia coli. A new approach in therapy to maintain remission in colonic Crohn's disease? J Clin Gastroenterol 1997; 25:653-658.
53. Prantera C, Scribano ML, Falasco G, Andreoli A, Luzi C: Ineffectiveness of probiotics in preventing recurrence after curative resection of Crohn's disease: a randomised controlled trial with Lactobacillus GG. Gut 2002; 51:405-409.
54. Schultz M, Timmer A, Herfarth HH, Sartor RB, Vanderhoof JA, Rath HC: Lactobacillus GG in inducing and maintaining remission of Crohn's disease. BMC Gastroenterology 2004; 4:1-4.
55. Campieri M, Rizzello F, Venturi A, Poggioli G, Ugolini U, Amadini C y cols.: Combination of antibiotic and probiotic treatment is efficacious in prophylaxis of post-operative recurrence of Crohn's disease; a randomized controlled study vs mesalamine (abstract). Gastroenterology 2000; 118:A4279.
56. Rutgeerts P, D'Haens G, Baert F Van Assche M, Noman I, Aerden S y cols.: Randomized placebo controlled trial of pro-and prebiotics (Synbiotics cocktail) for maintenance of infliximab induced remission of luminal Crohn's disease (CD). Gastroenterology 2004; 126:A-467 (T1310).
57. Guslandi M, Mezzi G, Sorghi M, Testoni PA: Sacharomyces boulardi in maintenance treatment of Crohn's disease. Dig Dis Sci 2000; 45:14662-1464.
58. Kruiz W, Schutz E, Fric P, Fixa B, Judmaier G, Stolte M: Double-blind comparison of an oral Escherichia coli preparation and meselazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 1997; 11:853-858.
59. Rembacken BJ, Snelling AM, Hawkey PM, Chalmers DM, Axon AT: Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet 1999; 354:635-639.
60. Kruiz W, Fric P, Stolte M: Maintenance of remission in ulcerative colitis is equally effective with Escherichia coli Nissle 1997 and with standard mesalamine. Gastroenterology 2001; 120:A139.
61. Faubion WA, Sandborn WJ: Probiotic therapy with E coli for ulcerative colitis. Take the good with the bad. Gastroenterology 2000; 118:650-655.
62. Venturi A, Gionchetti P, Rizzello F, Johansson R, Zucconi E, Brigidi P y cols.: Impact on the composition of the faecal microbiota by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment Pharmacol Ther 1999; 13:1103-1108.
63. Pathmakanthan S, Walsh M, Bengmark S y cols.: Efficacy and Tolerability treating acute distal ulcerative colitis with synbiotic enema's: a Pilot Trial. Abstract. Gut 2002; 51(Supl. lIII): A307.
64. Kuisma J, Mentula S, Jarvinen H, Kahri A, Saxelin M, Farkkila M: Effect of Lactobacillus rhamnosus GG on ileal pouch inflammation and microbial microbiota. Aliment Pharmacol Ther 2001; 17:509-515.
65. Gosselink MP, Schouten WR, Van Lieshout LMC, Hop WCJ, Laman JD, Ruseler-Van Embden JGH: Delay of first onset of pouchitis by oral intake of the probiotic strain Lactobacillus rhamnosus GG. Dis Colon Rectum 2004; 47:876-884.
66. Gionchetti P, Rizzello F, Venturi A, Brigidi P, Matteuzzi D, Bazzocchi G y cols.: Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 2000; 119:305-309.
67. Mimura T, Helwig U, Paggioli G, Schreiber S, Talbot IC, Nicholls RJ y cols.: One daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut 2004; 53:108-114.
68. Gionchetti P, Rizzello F, Helwig U, Venturi A, Lammers KM, Brigidi P y cols.: Prophylaxis of pouchitis onset with probiotic therapy: a double-bland, placebo-controlled trial. Gastroenterology 2003; 124:1202-1209.
69. Stanghellini BG, De Giorgio R, Cremon C, Cottrell GS, Santini D, Pasquinelli G y cols.: Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology 2004; 126:693-702.
70. Uribe A, Alam M, Johansson O, Midtvedt T, Theodorsson E: Micromicrobiota modulates endocrine cells in gastrointestinal mucosa of the rat. Gastroenterology 1994; 107:1259-1269.
71. O'Sullivan MA, O'Morain CA: Bacterial supplementation in the irritable bowel syndrome. A randomised double-blind crossover study. Digestive and Liver Disease 2000; 32:294-301.
72. O'Mahony L, McCarthy J, Kelly P, Hurley G, Luo F, Chen K y cols.: A randomized placebo-controlled, double-blind comparison of the probiotic bacteria lactobacillus and bifodobacterium in irritable bowel syndrome (IBS): symptom responses and relationship to cytokine profiles. ?????? In press.
73. Saggioro A: Probiotics in the treatment of irritable bowel syndrome. J Clin Gastroenterol 2004; 38 (Supl. 2):S104-S106.
74. Kim HJ, Camilleri M, McKinzie S, Lempke MB, Burton DD, Thomforde GM, Zinsmeister AR: A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrheoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2003; 17:895-904.
75. Niedzielin K, Kordecki H, Birkenfeld B: A controlled, doubleblind, randomised study on the efficacy of Lactobacillus plantarum 299 in patients with irritable bowel syndrome. Europ J Gastroentrol Hepatol 2001; 13:1143-1147.
76. Nobaek S, Johansson M-L, Molin G, Ahrne S, Jeppsson B: Alteration of intestinal micromicrobiota is associated with reduction in abdominal bloating and pain in patients with irritable syndrome. Am J Gastroenterol 2000; 95:1231-1238.
77. Sen S, Mullan MM, Parker TJ, Woolner JT, Tarry SA, Hunter JO: Effect of lactobacillus plantarum 299v on colonic fermentation and symptoms of Irritable bowel syndrome. Dig Dis Scien 2002; 47:2615-2620.
78. Marteau P, Minekus M, Havenaar R, Huis in't Veld JH: Survival of lactic acid bacteria in a dynamic model of the stomach and small intestine: validation and the effects of bile. J Dairy Sci 1997; 80:1031-1037.
79. Lorca GL, Wadström T, Fond de Valdez G, Ljungh Å: Lactobacillus acidophilus autolysins inhibit Helicobacter pylori in vitro. Curr Microbiol 2001; 42:39-44.
80. Canducci F, Armuzzi A, Cremonini F Cammarota G, Bartolozzi F, Pola P y cols.: A lyophilised and inactivated culture of Lactobacillus acidophilus increases Helicobacter pylori eradication rates. Aliment Pharmacol Ther 2000; 14:1625-1629.
81. Armuzzi A, Cremonini F, Ojetti V, Bartolozzi F, Canducci F, Candelli M y cols.: Effect of Lactobacillus GG supplementation on antibiotic-associated gastrointestinal side effects during Helicobacter pylori eradication therapy: a pilot study. Digestion 2001; 63:1-7.
82. Armuzzi A, Cremonini F, Bartolozzi F, Canducci F, Candelli M, Ojetti V y cols.: The effect of oral administration of Lactobacillus GG on associated gastrointestinal side effects during Helicobacter eradication. Aliment Pharmacol Ther 2001; 15:163-169.
83. Michetti P, Dorta G, Wiesel PH, Brassart D, Verdú E, Herranz M y cols.: Effect of whey based culture supernatant of Lactobacillus acidophilus (jonsonii) La-1 on Helicobacter pylori infections in humans. Digestion 1999; 60:203-209.
84. Felley CP, Corthesy-Theulaz I, Rivero JL, Sipponen P, Kaufmann M, Bauerfeind P y cols.: Favourable effects of an acidified milk (La-1) on Helicobacter pylori gastritis in man. Eur J Gastroenterol Hepatol 2001; 13:25-29.
85. Cremonini F, Di Caro S, Covino M, Armuzzi A, Gabrielli M, Santarelli L y cols.: Effect of different probiotic preparations on anti-helicobacter pylori therapy-related side effects: a parallel group, triple blind, placebo-controlled study. Am J Gastroenterol 2002; 97:2744-2749.
86. Wang KY, Li SN, Liu CS, Perng DS, Su YC, Wu DC y cols.: Effects of ingesting Lactobacillus- and Bifidobacterium-containing yogurt in subjects with colonized Helicobacter pylori. Am J Clin Nutr 2004; 80:737-741.
87. Riordan SM, Skinner N, Nagree A, McCallum H, McIver CJ, Kurtovic J y cols.: Peripheral blood mononuclear cell expression of toll-like receptors and relation to cytokine levels in cirrhosis. Hepatology 2003; 37:1154-1164.
88. Qing Liu,Zhong Ping Duan, Da Kang Ha, Bengmark S, Kurtovic J, Riordan SM: Synbiotic modulation of gut microbiota: effect on minimal hepatic encephalopathy in patients with liver cirrhosis. Hepatology 2004; 39:1441-1449.
89. Kurtovic J,Ruettimann U, Adamson H, Bengmark S, Williams R, Riordan SM: Improvement in indocyanine green clearance following synbiotic treatment in cirrhosis. Gut 2003; 52 (Supl.): A3.
90. Rayes N, Hansen S, Seehofer D, Boucsein K, Müller AR, Serke S y cols.: Early enteral supply of Lactobacillus and fibre vs selective bowel decontamination (SBD) - a controlled trial in liver transplant recipients. Transplantation 2002; 74:123-127.
91. Rayes N, Seehofer D, Theruvath T. Settmacher U, Jonas S, Bengmark S y cols.: Combined perioperative enteral supply of bioactive pre- and probiotics abolishes postoperative bacterial infections in human liver transplantation - a randomised, double blind clinical trial. Am J Transplant 2005; 5:125-130.
92. Rayes N, Hansen S, Boucsein K y cols.: Early enteral supply of fibre and lactobacilli vs parenteral nutrition - a controlled trial in major abdominal surgery patients. Nutrition 2002; 18:609-615.
93. Woodcock NP, McNaught CE, Morgan DR, Gregg KL, MacFie J: An investigation into the effect of a probiotic on gut immune function in surgical patients. Clin Nutr 2004; 23:1069-1073.
94. Oláh A, Belágyi T, Issekutz Á y cols.: Early Enteral Nutrition with Specific Lactobacillus and Fibre reduces Sepsis in Severe Acute Pancreatitis. British Journal of Surgery 2002: 89:1103-1107.
95. Kompan L, Kremzar B, Gadzijev E, Prosek M: Effects of early enteral nutrition on intestinal permeability and the development of multiple organ failure after multiple injury. Intensive Care Med 1999; 25:129-130.
96. Mangiante G, Colucci G, Marinello P y cols.: Bengmark's self-propelling naso-jejunal tube: a new useful device for intensive enteral nutrition. Int Care Med 1998; 24:abstract 330.
97. Karsenti D, Viguiler J, Bourlier P, D'Alteroche L, Barbieux JP, Metman EH y cols.: Enteral nutrition during acute pancreatitis. Feasibility study of a self-propelling spiral distal end jejunal tube. Gastroenterol Clin Biol 2003; 27:614-617.
98. Lai CWY, Barlow R, Barnes M, Hawthorne AB: Bedside placement of nasojejunal tubes: a randomized-controlled trial of spiral - vs straight-ended tubes. Clin Nutr 2003; 22:267-270.
99. Motivala SJ, Sarfatti A, Olmos L, Irwin MR: Inflammatory markers and sleep disturbance in major depression. Psychosom Med 2005; 67:187-194.
100. Knight DJW, Ala'Aldeen D, Bengmark S, Girling KJ: The Effect of Synbiotics on Gastrointestinal Microbiota in the Critically ill. Brit J Anaesth 2004; 92:307P-308P.